Prevalere Life Sciences: Protocol driven

Source: Healthcare Exec

Date :11/12/2007 08:43:52

Chief Executive Officer Mario Rocci talks us through the unique, customer focused vision of contract research organization (CRO) Prevalere Life Sciences.

Written by Roxanne Ridge and Produced by Thomas Venturo

Prevalere Life Sciences, Inc. emerged from Oneida Research Services, Inc. (ORS) in 2002. ORS was started in the 70s as a microelectronics testing firm, and later branched out into pharmaceutical testing during the 80s. Naturally, as time went on it made sense to focus on the two areas separately.

Prevalere provides consulting and GLP/GMP compliant analytical testing services to biotechnology and pharmaceutical companies. The company draws on the extensive product development expertise of a team of consultants to provide guidance in the preparation of IND applications for biotechnology products under development. In addition, Prevalere provides analytical testing support during the development stages of biotechnology and pharmaceutical products.

Since starting up, Prevalere has worked successfully to support the approvals of several important new drugs – many of which were developed to treat the most deadly of diseases including Alzheimer’s, AIDS, cancer and heart disease.

Work ethics

Over the last several years, Prevalere has grown quickly to its current size of approximately 100 employees, at its Whitesboro, NY site.

And for Mario Rocci, Prevalere’s CEO, this location is everything. Mario earned a Ph.D. in Pharmaceutics and a B.S. in Pharmacy from the State University of New York at Buffalo. He gained his initial drug development experience working with a team of Clinical Pharmacologists as the Head of the Laboratory for Investigative Medicine at Thomas Jefferson University. He then joined Oneida Research Services in 1988 as the Director of their pharmaceutical services group.

“I grew up in the Mohawk Valley,” says Mario. “And I always wanted to come back here to work. “I liked the idea that the company…

To read the full article, click here